Which peptides are people actually buying and injecting right now?

Note on evidence distribution: despite the brief asking for a US/UK/East Asia comparison, the supplied findings are heavily US-centric (X, Reddit, YouTube, LinkedIn) with large Xiaohongshu (92 items), Zhihu (61), WeChat (25), and Douyin (35) clusters logged in the stats but not surfaced with quotable content beyond one Zhihu item — so genuine cross-region comparison isn't possible from what's here. No Weibo content was captured at all. UK-specific consumer voices are also absent. This brief is therefore mostly a US gray-market picture with a single China data point, not a full three-region comparison — flagged rather than papered over.

1. The same short list of compounds recurs across every US consumer account — BPC-157, TB-500, ipamorelin, CJC-1295, and MOTS-c — run together as "stacks," not single-agent trials (seen across 3 sources: X self-reports [1][2][3], a clinician taxonomy naming the identical compounds [15], and Zhihu naming the same trio as China's "网红肽"/influencer peptides [8]). This is the strongest cross-platform agreement in the dataset: buyers, clinicians describing the market, and Chinese commentary all converge on the same handful of named substances.

2. Chinese suppliers dominate the gray-market supply chain, and independent testing puts the mislabeling/adulteration rate at roughly 20-40% (seen across 3 sources: The Guardian's on-the-ground reporting citing ~20% failure from independent labs [6], a YouTuber's own $800 lab test finding one compound ~40% adulterated while another passed at 98.2% purity [5], and Starlight Peptides describing China as the "dominant" but riskiest source [7]). This is treated by buyers less as a scandal and more as a known cost of doing business.

3. Buyers have built their own informal quality-control and vendor-vetting infrastructure — Telegram vendor lists, purity thresholds, and reship guarantees — entirely outside clinical or regulatory channels (emerging agreement, 2 sources: a buyer describing Telegram groups of ~20 vendors and asking whether they'll "reship if it gets seized at customs" [9], and a separate video walking through buyer-run HPLC/mass-spec testing treating sub-95% purity as a red flag [10]). This DIY-regulator behavior is a distinctly crowd-generated detail absent from mainstream "is it safe" coverage.

4. Clinician and physician voices frame the lack of safety testing as the deliberate business model of the gray market, not an oversight (loud but unconfirmed — single heavily-engaged source: a physician-commentator's viral X post arguing sellers profit specifically because they skip the ~$1B approval process, and "you're buying the risk they refuse to remove" [13]), reinforced by a separate LinkedIn account of FDA staff reportedly recommending against all seven peptides under review despite a projected $30B market [11].

5. Self-injection has become a normalized at-home ritual in the US, with buyers describing bathroom/kitchen setups and social-media "obsession" posts rather than doctor visits (loud but unconfirmed — single source, The Guardian video [6]), consistent with a separate LinkedIn practitioner's warning that peptide talk has moved "from research labs into gyms, group chats and bathroom cabinets" [12] (emerging agreement, 2 sources).

6. Stacking scale can be extreme — one self-experimenter reports running 12 different peptides concurrently in a single "cycle" (loud but unconfirmed — single Reddit post [4]), consistent in spirit with the multi-compound X stacks above, suggesting this may be a wider pattern the current dataset only lightly captures.

7. A political/celebrity angle is emerging: buyers reportedly source retatrutide — the peptide Trump is said to be taking under "compassionate use" — labeled as a "research chemical" to sidestep prescription requirements (loud but unconfirmed — single Bluesky post [14]), with the poster noting this particular batch tested as advertised, cutting against assumptions that all gray-market product is compromised.

Regional gap: the brief's request to compare US, UK, and East Asia sentiment is only partially answerable — Xiaohongshu (92 items) and WeChat (25 items) were logged with volume but essentially no quotable consumer content came through in this pull, and Weibo returned nothing. The one Zhihu item available shows Chinese-language commentary using near-identical framing to US clinicians (naming the same three "hot" peptides as unapproved), suggesting shared discourse rather than a distinct regional narrative — but this is far too thin to call a pattern.